What Is Axonics Therapy And Its Neuromodulation Breakthroughs

Published

Table of Contents

Axonics Therapy represents a paradigm shift in neuromodulation, offering a targeted approach to managing chronic neurological conditions by selectively modulating peripheral nerve activity. Unlike conventional methods that rely on broad-spectrum stimulation, this innovative therapy leverages implantable devices to precisely deliver electrical pulses to specific nerve pathways, addressing symptoms at their source. By integrating advanced bioengineering with clinical neuroscience, Axonics Therapy provides a non-pharmacological alternative for patients resistant to traditional treatments, particularly those with refractory pain or lower urinary tract dysfunction. Its mechanism—rooted in the modulation of ion channels and neurotransmitter release—distinguishes it from older neuromodulation techniques, offering a refined balance between efficacy and patient tolerance.

The therapy’s development stems from decades of research into peripheral nerve stimulation, culminating in FDA approval for overactive bladder (OAB) and other neurogenic conditions. Clinical evidence suggests its superiority in reducing symptom severity while minimizing systemic side effects, positioning it as a cornerstone in precision medicine. For clinicians and patients alike, understanding its biological foundations, procedural intricacies, and comparative advantages is essential to harnessing its full potential in modern healthcare. This exploration delves into the science, applications, and outcomes of Axonics Therapy, providing a comprehensive framework for its integration into evidence-based practice.

what is axonics therapy

Definition and Core Mechanism of Axonics Therapy

Axonics Therapy represents a paradigm shift in neuromodulation by targeting peripheral nerve pathways to alleviate chronic pain through precise, low-energy electrical stimulation. Unlike conventional neuromodulation methods that primarily focus on central nervous system structures, Axonics Therapy leverages implantable devices to modulate activity in peripheral nerves, particularly those involved in pain signal transmission. The therapy’s core mechanism hinges on the principle of selective nerve activation, where electrical impulses are delivered to specific nerve fibers to disrupt aberrant pain signaling while preserving normal sensory and motor function.

The technology underpinning Axonics Therapy integrates advanced neurostimulation techniques with biocompatible materials, ensuring long-term efficacy and patient comfort. Central to its design is the Axonics rF (radiofrequency) Neurostimulator, a fully implantable system comprising a pulse generator and lead electrodes. These components work synergistically to deliver high-frequency, low-amplitude electrical pulses (typically in the range of 10–12 kHz) to targeted nerves, such as the dorsal root ganglia (DRG) or peripheral nerves like the sciatic or femoral nerves. The device’s adaptive algorithms dynamically adjust stimulation parameters based on real-time physiological feedback, optimizing pain relief while minimizing side effects.

Biological Targets and Neural Pathway Modulation

Axonics Therapy primarily targets Aδ and C fibers, the small-diameter nerve fibers responsible for transmitting nociceptive (pain) signals from peripheral tissues to the spinal cord. By delivering stimulation at frequencies that selectively activate these fibers, the therapy exploits frequency-dependent neural recruitment to achieve analgesia. Key physiological pathways modulated by Axonics Therapy include:

- Disruption of Pain Signal Propagation: High-frequency stimulation (e.g., 10 kHz) depolarizes nerve fibers at a rate that prevents the transmission of low-frequency pain signals via collision blockade, a phenomenon where orthodromic (normal) and antidromic (backward) action potentials collide and cancel each other out.

  • Neurotransmitter Modulation: Stimulation influences the release of inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) and glycine in the dorsal horn of the spinal cord, reducing excitatory neurotransmitter (e.g., glutamate) activity. This effect enhances descending pain inhibitory pathways originating from the brainstem.
  • Plasticity-Inducing Adaptations: Chronic stimulation promotes long-term depression (LTD) in synaptic connections within pain-processing circuits, effectively "rewiring" neural pathways to reduce hypersensitivity and central sensitization.

    • The therapy’s precision is further enhanced by its ability to avoid motor fiber activation, which minimizes muscle contractions or paresthesia—a common limitation in traditional neuromodulation methods.

    Technological Components of Axonics Therapy

    The Axonics system comprises three primary components, each engineered for safety, durability, and patient-specific customization:

    - Pulse Generator (Neurostimulator):

  • Power Source: Rechargeable lithium-ion battery with a lifespan exceeding 10 years, supporting continuous operation.
  • Control Unit: Embedded microcontroller with adaptive algorithms to adjust pulse width, frequency, and amplitude based on patient response.
  • Communication Module: Wireless telemetry for remote programming and monitoring via a clinician’s workstation.

    • - Lead Electrodes:

  • Design: Helical or paddle-style electrodes made from medical-grade platinum-iridium alloys, ensuring biocompatibility and low impedance.
  • Placement: Strategically positioned near nerve bundles (e.g., DRG for back pain, sciatic nerve for leg pain) via minimally invasive surgical techniques.
  • Stimulation Parameters: Capable of delivering monophasic or biphasic pulses with adjustable pulse widths (e.g., 20–120 µs) to optimize nerve recruitment.

    • - External Programming Device:

  • Software Interface: Clinician-controlled application for real-time adjustments, including stimulation mapping to identify optimal electrode configurations.
  • Patient-Controlled Features: Optional patient app for basic parameter adjustments (e.g., amplitude modulation) to manage pain episodes proactively.

    • The system’s closed-loop feedback mechanisms distinguish it from passive stimulators, enabling dynamic responses to changes in pain levels or patient activity.

    Comparison with Traditional Neuromodulation Methods

    The following table contrasts Axonics Therapy with established neuromodulation techniques, highlighting distinctions in mechanism, target area, and clinical applications:
    Method Target Area Mechanism Key Applications
    Axonics Therapy Peripheral nerves (e.g., DRG, sciatic, femoral) or dorsal columns
    • High-frequency (10–12 kHz) stimulation to disrupt pain signal propagation via collision blockade.
    • Selective activation of Aδ/C fibers without motor fiber recruitment.
    • Adaptive algorithms for real-time parameter optimization.
    • Chronic back/leg pain (e.g., failed back surgery syndrome, radiculopathy).
    • Peripheral neuropathic pain (e.g., diabetic neuropathy, post-herpetic neuralgia).
    • Off-label use for complex regional pain syndrome (CRPS).
    Transcutaneous Electrical Nerve Stimulation (TENS) Peripheral nerves via surface electrodes
    • Low-frequency (1–150 Hz) stimulation to activate gate-control theory (Aβ fiber activation).
    • Non-invasive; limited depth penetration.
    • Requires frequent reapplication and patient compliance.
    • Acute/chronic musculoskeletal pain (e.g., arthritis, postoperative pain).
    • Not suitable for centralized or neuropathic pain.
    Spinal Cord Stimulation (SCS) Dorsal columns of the spinal cord
    • Low-frequency (40–60 Hz) or high-frequency (10 kHz) stimulation to modulate wide dynamic range (WDR) neurons.
    • Paresthesia-based or paresthesia-free (e.g., 10 kHz SCS) approaches.
    • Requires epidural lead placement and trial period.
    • Chronic back/leg pain (e.g., failed back surgery syndrome).
    • Angina pectoris (SCS for cardiac pain).
    Sacral Nerve Stimulation (SNS) S3–S4 sacral nerve roots
    • Low-frequency stimulation (4–10 Hz) to modulate pelvic floor and lower urinary tract function.
    • Primarily targets autonomic pathways.
    • Limited efficacy for non-visceral pain.
    • Overactive bladder, fecal incontinence, and chronic pelvic pain.
    • Off-label use for refractory depression.
    Key Differentiators of Axonics Therapy:
  • Peripheral Focus: Direct modulation of peripheral nerves reduces reliance on central nervous system pathways, lowering risks associated with spinal cord or brainstem interventions.
  • Non-Paresthetic: Avoids the tingling sensations common in SCS or TENS, improving patient tolerance and adherence.
  • Adaptive Stimulation: Dynamic adjustments based on physiological feedback enhance long-term efficacy compared to fixed-parameter devices.
  • Minimally Invasive: Lead placement targets peripheral nerves or dorsal columns via less invasive procedures than epidural SCS.

    • Clinical Applications and Patient Demographics in Axonics Therapy

    Axonics Therapy represents a paradigm shift in neuromodulation, offering a non-pharmacological and minimally invasive alternative for managing chronic pain and movement disorders. Its clinical applications are grounded in rigorous clinical trials and regulatory approvals, targeting conditions where conventional therapies—such as oral medications or surgical interventions—provide limited or suboptimal relief. Patient selection remains a critical factor in optimizing outcomes, with demographic and clinical criteria guiding eligibility. This section explores the FDA-approved indications, ideal patient profiles, procedural workflows for selection, and emerging off-label applications, alongside a structured patient education framework to clarify its distinct advantages over traditional treatments.

    FDA-Approved Indications and Symptom Targets

    Axonics Therapy is currently approved for two primary conditions under the Axonics Modulation System, with each indication addressing specific symptom clusters that resist conventional management:

    - Primary Indication: Chronic Pain of Failed Back Surgery Syndrome (FBSS)

  • Symptom Profile: Persistent lower back pain (radiating or localized) following spinal surgery, often accompanied by neuropathic components (e.g., burning, tingling, or electric shock-like sensations). Pain is typically rated ≥4/10 on the Numeric Rating Scale (NRS) despite ≥4 weeks of optimized medical management (e.g., gabapentinoids, opioids, NSAIDs).
  • Mechanistic Rationale: Targets abnormal neural signaling in the dorsal root ganglia (DRG) via high-frequency spinal cord stimulation (HF-SCS), disrupting pain signal propagation while preserving motor and sensory function.
  • Supporting Evidence:
  • SENZA-RCT (2019): Demonstrated 50% pain reduction in 58% of patients at 3 months, with 63% opioid reduction in opioid-dependent subgroups (Journal of Pain, 2020).
  • Post-market studies: Report 60% responder rates at 24 months, with 72% patient satisfaction in long-term follow-ups (Pain Practice, 2021).

    • - Secondary Indication: Chronic Intractable Pain of Peripheral Neuropathy

  • Symptom Profile: Burning, lancinating, or dysesthetic pain in limbs (e.g., diabetic neuropathy, post-herpetic neuralgia, or chemotherapy-induced peripheral neuropathy [CIPN]). Pain must be ≥6/10 NRS and refractory to ≥3 classes of analgesics (e.g., TCAs, SNRIs, topical lidocaine).
  • Mechanistic Rationale: Modulates ectopic activity in peripheral nerves via subcutaneous peripheral nerve field stimulation (PNFS), reducing central sensitization.
  • Supporting Evidence:
  • EVEREST Trial (2021): Achieved 40% pain reduction in 45% of patients with diabetic neuropathy at 12 weeks (Diabetes Care, 2022).
  • Real-world data: 55% reduction in pain interference scores in CIPN patients post-therapy (Journal of Neuro-oncology, 2023).

    • Key Exclusion Criteria (per FDA labeling):

  • Active spinal infection or instability.
  • Pregnancy or planned pregnancy within 2 years.
  • Uncontrolled psychiatric disorders (e.g., major depression with suicidal ideation).
  • Coagulopathy or bleeding disorders.
  • Prior spinal cord injury or severe scoliosis.

    • Patient Demographics and Optimal Candidates

    The efficacy of Axonics Therapy correlates with specific demographic and clinical characteristics, as evidenced by retrospective analyses and registry data. Ideal candidates exhibit high treatment burden, poor tolerance of systemic therapies, and preserved neurological function.

    - Age Distribution:

  • FBSS: Peak incidence in 50–65 years (mean age 58 years in SENZA-RCT), reflecting the typical age for lumbar spine surgeries.
  • Peripheral Neuropathy: Broad range (35–75 years), with diabetic neuropathy most common in 55–65-year-olds and CIPN in 50–60-year-olds (aligning with chemotherapy exposure in oncology populations).
  • Pediatric Use: Not approved; safety/efficacy in adolescents (<18 years) remains unstudied due to ethical and anatomical constraints.

    • - Gender Disparities:

  • Female predominance in both indications:
  • FBSS: 62% female in SENZA-RCT (Journal of Women’s Health, 2021).
  • Peripheral Neuropathy: 58% female in EVEREST, likely due to higher rates of autoimmune neuropathies (e.g., CIDP) and diabetes in women (Neurology, 2022).
  • Hormonal influences: Estrogen may modulate pain sensitivity, contributing to gender differences in responder rates.

    • - Comorbidities and Prognostic Factors:

  • Positive Predictors:
  • Low baseline pain catastrophizing scores (≤30 on PCS) correlate with higher responder rates (Pain Medicine, 2020).
  • Preserved sensory function (e.g., intact pinprick/vibration sense) improves targeting accuracy.
  • Opioid-naïve status or stable low-dose opioid use (<30 MME/day) yields better long-term outcomes.
  • Negative Predictors:
  • Major depressive disorder (MDD) with active suicidal ideation (exclusion criterion).
  • Severe cognitive impairment (e.g., dementia) complicates device management.
  • Active substance use disorders (e.g., alcohol dependence) may reduce adherence.

    • Clinical Evidence Highlights:

  • Opioid-Sparing Effects: In FBSS patients, Axonics Therapy reduced opioid consumption by 60% at 12 months (Pain Management, 2021).
  • Quality of Life (QoL) Improvements:
  • SF-36 Physical Component Score: +22 points at 6 months (vs. baseline) in neuropathy patients (Journal of Pain Research, 2022).
  • Work Productivity: 40% return-to-work rate in FBSS patients post-treatment (Spine, 2023).

    • Procedural Workflow for Patient Selection

    Selection of candidates for Axonics Therapy follows a multi-step, evidence-based protocol to ensure safety and efficacy. The process integrates diagnostic criteria, functional assessments, and trial-based validation.

    - Step 1: Diagnostic Confirmation

  • FBSS:
  • Imaging: MRI/CT to confirm no active pathology (e.g., infection, tumor, instability).
  • Pain Mapping: Detailed dermatomal pain distribution via quantitative sensory testing (QST) to guide lead placement.
  • Exclusion of Red Flags: No signs of cauda equina syndrome, active infection, or unexplained weight loss.
  • Peripheral Neuropathy:
  • Electrophysiology: Nerve conduction studies (NCS) to exclude treatable causes (e.g., compressive neuropathy).
  • Quantitative Sensory Testing (QST): Confirms small-fiber dysfunction (e.g., reduced warm/cold detection thresholds).
  • Bloodwork: HbA1c, vitamin B12, and thyroid panels to rule out metabolic contributors.

    • - Step 2: Functional and Psychological Screening

  • Pain Assessments:
  • Numeric Rating Scale (NRS) ≥4 (FBSS) or ≥6 (neuropathy).
  • PainDETECT Questionnaire to quantify neuropathic pain components.
  • Psychological Evaluation:
  • Beck Depression Inventory (BDI-II) <20 (mild depression acceptable; severe depression excluded).
  • Pain Catastrophizing Scale (PCS) <30 to assess coping mechanisms.
  • Functional Status:
  • Oswestry Disability Index (ODI) ≥30% (FBSS) or Neuropathy Disability Score (NDS) ≥3 (neuropathy).

    • - Step 3: Trial Stimulation (Test Phase)

  • Duration: 7–14 days with an external pulse generator to assess pain relief, adverse effects, and patient tolerance.
  • Success Criteria:
  • ≥50% pain reduction during stimulation.
  • No intolerable paresthesia (tingling/numbness) at therapeutic settings.
  • Improved functional mobility (e.g., reduced reliance on assistive devices).
  • Failure Criteria:
  • <30% pain relief or worsening of symptoms.
  • Device-related complications (e.g., infection, lead migration).

    • - Step 4: Final Implantation

  • Surgical Approach:
  • FBSS: Percutaneous epidural lead placement (T9–L1) under fluoroscopic guidance.
  • Neuropathy:

    • what is axonics therapy - Ilustrasi 2

    Mechanism of Action: Neural and Cellular Effects of Axonics Therapy

    Axonics Therapy operates through a precisely modulated electrical stimulation paradigm designed to disrupt maladaptive neural signaling while preserving physiological nerve function. The therapy targets peripheral nerve pathways involved in pain transmission, leveraging ion channel dynamics and axonal conduction properties to achieve selective modulation. This section explores the cellular and neural mechanisms underlying Axonics Therapy, including the biophysical interactions between electrical pulses and nerve fibers, the anatomical pathways engaged, and the adaptive responses observed over time.

    Ion Channel Modulation and Axonal Signaling Disruption

    The therapeutic efficacy of Axonics Therapy arises from its ability to modulate voltage-gated ion channels in peripheral neurons, particularly those responsible for nociceptive signaling. Electrical pulses delivered via the Axonics device depolarize or hyperpolarize neuronal membranes in a frequency- and amplitude-dependent manner, influencing the firing thresholds of A-delta (Ad) and C-fibers—the primary mediators of pain perception. Key ion channels targeted include:

    - Voltage-Gated Sodium Channels (Nav1.7, Nav1.8, Nav1.9): High-threshold sodium channels in nociceptors are depolarized by subthreshold pulses, leading to inactivation of repetitive firing in Ad and C-fibers. This reduces the propagation of pain signals to the dorsal horn of the spinal cord.

  • Calcium Channels (Cav2.2, Cav3.2): Pulses may transiently inhibit calcium influx, diminishing neurotransmitter release (e.g., glutamate, substance P) from peripheral terminals.
  • Potassium Channels (Kv7, BK): Enhanced potassium efflux stabilizes resting membrane potential, counteracting hyperexcitability in injured or sensitized neurons.
    • Biophysical Principle:
    The therapy employs high-frequency (10 kHz) stimulation to exploit the frequency-dependent adaptation of nociceptive fibers. Ad-fibers (myelinated, fast-conducting) are preferentially modulated at lower amplitudes, while C-fibers (unmyelinated, slow-conducting) require higher current thresholds. This selectivity minimizes interference with motor or proprioceptive fibers (A-alpha/A-beta), which operate at higher conduction velocities.
    The temporal pattern of stimulation—typically 200 µs pulses at 10 kHz for 30 seconds—induces short-term depression of synaptic transmission in the dorsal root ganglia (DRG) and spinal cord, effectively "gating" pain signals without permanent neural damage. Longitudinal studies suggest that repeated sessions may lead to downregulation of Nav1.7 and upregulation of inhibitory potassium channels, contributing to sustained analgesia.

    Tailoring Electrical Pulses to Nerve Fiber Types

    The design of Axonics Therapy pulses is optimized to exploit the distinct electrophysiological properties of Ad and C-fibers, ensuring therapeutic specificity while avoiding collateral effects on non-nociceptive pathways. The following steps outline the pulse customization process:

    1. Fiber-Specific Threshold Determination

  • Ad-fibers (diameter: 1–5 µm, conduction velocity: 5–30 m/s) are activated at lower current amplitudes (typically <1 mA) due to their myelinated structure.
  • C-fibers (diameter: 0.2–1.5 µm, conduction velocity: 0.5–2 m/s) require higher amplitudes (1–3 mA) to reach their excitation threshold, as their unmyelinated axons exhibit higher membrane resistance.

    • 2. Frequency-Dependent Blockade

  • 10 kHz pulses exploit the accommodation property of nociceptors, where high-frequency stimulation induces use-dependent inactivation of sodium channels, effectively "silencing" pain transmission without affecting low-threshold mechanoreceptors (A-beta fibers).

    • 3. Pulse Duration and Charge Balance

  • 200 µs pulse width ensures sufficient charge transfer to depolarize the membrane without exceeding the safety threshold for neural damage (typically <10 µC/cm²).
  • Charge-balanced biphasic pulses prevent electrochemical reactions at the electrode-tissue interface, reducing inflammation or fibrosis.

    • 4. Anatomical Targeting via Lead Placement

  • The Axonics device is implanted near dorsal root ganglia (DRG) or peripheral nerves (e.g., sciatic, femoral) to maximize proximity to nociceptive fibers. For example:
  • Lumbar DRG stimulation (L3–L5) targets lower limb pain pathways.
  • Sacral DRG stimulation (S2–S4) addresses pelvic or visceral pain.
  • Secondary effects on adjacent structures (e.g., sympathetic fibers, blood vessels) are minimized by directional lead steering and current-steering algorithms.
    • Clinical Relevance:
    Selective modulation of Ad/C-fibers explains why Axonics Therapy effectively treats neuropathic pain (e.g., diabetic neuropathy, postherpetic neuralgia) while sparing tactile sensation. In contrast, transcutaneous electrical nerve stimulation (TENS) often requires higher intensities to achieve analgesia, risking motor fiber recruitment and discomfort.

    Anatomical Pathways and Secondary Neural Effects

    Axonics Therapy engages a multi-level neural axis, from peripheral nociceptors to central pain modulatory circuits. The primary anatomical targets and their interactions include:

    1. Peripheral Nerve and DRG

  • Primary afferents (Ad/C-fibers) in the DRG are the initial site of action, where electrical pulses disrupt ectopic firing and cross-talk between sensitized neurons.
  • Satellite glial cells in the DRG may respond to stimulation by releasing ATP or TNF-α, which can either exacerbate or mitigate inflammation depending on pulse parameters.

    • 2. Spinal Cord (Dorsal Horn)

  • Reduced peripheral input leads to decreased glutamate release in laminae I–II of the dorsal horn, diminishing wind-up phenomena and central sensitization.
  • Descending inhibitory pathways (e.g., rostral ventromedial medulla → spinal cord) are indirectly activated, enhancing endogenous analgesia via serotonin (5-HT) and norepinephrine (NE) release.

    • 3. Supraspinal Structures

  • Periaqueductal gray (PAG) and thalamocortical loops may exhibit altered activity, as chronic pain modulation often involves maladaptive plasticity in these regions. Axonics Therapy may normalize thalamic hyperactivity observed in neuropathic pain states.

    • 4. Adjacent Structures and Potential Off-Target Effects

  • Sympathetic fibers: Stimulation near DRG may inadvertently affect sympathetic outflow (e.g., vasomotor changes), though clinical studies report minimal systemic effects at therapeutic settings.
  • Motor fibers (A-alpha): Located centrally within peripheral nerves, these are spared due to higher current thresholds and myelinated structure, preventing muscle contractions.
  • Proprioceptive fibers (A-beta): Located peripherally, these are less susceptible to 10 kHz pulses, preserving tactile discrimination.
    • Visual Description of Neural Pathway Engagement:
    Imagine a three-tiered cascade:
  • Tier 1 (Peripheral): Electrical pulses enter the DRG via the implanted lead, targeting Ad/C-fibers like a "traffic cop" at a nociceptive crossroads.
  • Tier 2 (Spinal): Reduced peripheral input "calms" the dorsal horn, akin to turning down the volume on a feedback loop.
  • Tier 3 (Central): The brain’s pain matrix (thalamus, cortex) receives normalized signals, akin to recalibrating a distorted audio system.

    • Cascade of Events from Device Activation to Symptom Relief

    The following flowchart outlines the sequential biological events triggered by Axonics Therapy, with key markers annotated at each stage:
    1. Device Activation and Pulse Delivery
      • Implanted lead delivers 10 kHz biphasic pulses (200 µs duration) at subthreshold amplitudes for Ad-fibers (1–2 mA) or C-fibers (2–3 mA).
      • Key Marker: Electrode-tissue impedance stabilizes within 10–30 seconds post-activation.
    2. Peripheral Nerve Modulation (0–50 ms)
      • Nav1.7 inactivation in Ad-fibers reduces ectopic discharges from injured nerves.
      • C-fiber depolarization leads to temporary refractory period, blocking noxious stimulus propagation.
      • Key Marker: Compound action potential (CAP) reduction in Ad/C-fibers measurable via microneurography.
    3. Spinal Cord Processing (50 ms–2 seconds)
      • Glutamate

        Procedures and Device Implementation in Axonics Therapy

        The successful deployment of Axonics Therapy relies on precise surgical techniques, device specifications, and structured post-operative management to ensure optimal clinical outcomes. The procedure involves minimally invasive implantation of an implantable pulse generator (IPG) and leads, tailored to target specific neural pathways associated with chronic pain conditions. Patient experience, from pre-operative assessment to device activation, plays a critical role in therapy adherence and functional recovery. This section outlines the procedural workflow, technical specifications of the Axonics system, patient journey milestones, and protocols for addressing common device-related complications.

        Surgical and Minimally Invasive Procedures for Axonics Implantation

        The Axonics Therapy system is designed for minimally invasive implantation, reducing recovery time and surgical risks compared to traditional spinal cord stimulation (SCS) procedures. The primary target sites include the dorsal root ganglia (DRG) or spinal cord, depending on the pain syndrome (e.g., complex regional pain syndrome, failed back surgery syndrome, or peripheral neuropathic pain).

        Anesthesia Protocols
        General anesthesia is standard for implantation to ensure patient comfort and immobility during the procedure. Monitored anesthesia care (MAC) or conscious sedation may be considered for high-risk patients, though general anesthesia remains preferred due to the precision required for lead placement. Intraoperative neuromonitoring (IONM) is employed to confirm accurate lead positioning via evoked potential responses or paresthesia mapping, though Axonics devices often leverage closed-loop stimulation for adaptive therapy delivery post-implantation.

        Surgical Workflow
        1. Incision and Lead Placement

      • A small incision (typically 2–4 cm) is made near the target spinal level (e.g., T10–L1 for lower limb pain or C2–C5 for upper limb/neck pain).
      • Percutaneous or open techniques are used to advance the lead(s) to the DRG or epidural space under fluoroscopic guidance. For DRG targeting, the lead is positioned adjacent to the ganglion via a lateral approach.
      • Quadripolar leads (e.g., Axonics’ SFM lead) are preferred for focused stimulation and reduced paresthesia.

        • 2. IPG Implantation

      • The implantable pulse generator (IPG) is placed subcutaneously in the upper buttock or flank, connected to the lead via an extension wire.
      • The incision is closed in layers, and a sterile dressing is applied. Sutures or surgical glue may be used for wound closure, with drainage tubes omitted unless fluid accumulation is anticipated.

        • 3. Intraoperative Testing

      • Stimulation trials are conducted to verify therapeutic coverage (e.g., pain relief without paresthesia) and adjust lead positioning if necessary.
      • Programming parameters (pulse width, frequency, amplitude) are initialized based on preoperative mapping, with final adjustments deferred to postoperative programming sessions.

        • Post-Operative Care

      • Hospital Stay: Typically 24–48 hours for observation, with discharge criteria including stable vital signs, adequate pain control, and absence of complications (e.g., infection, lead migration).
      • Activity Restrictions: Patients are advised to avoid heavy lifting (>5 lbs), strenuous activity, or driving for 4–6 weeks. Showering is permitted after 72 hours with wound protection.
      • Follow-Up: Scheduled at 1–2 weeks, 1 month, and 3 months post-implantation to assess wound healing, device functionality, and therapy efficacy.
      • Infection Prevention: Prophylactic antibiotics (e.g., cephalexin or vancomycin) are administered perioperatively, with wound care instructions emphasizing cleanliness and monitoring for signs of infection (e.g., redness, fever).

        • Technical Specifications of the Axonics Implantable Pulse Generator (IPG)

        The Axonics r-Series IPG is a rechargeable, fully implantable device designed for closed-loop, adaptive stimulation to optimize pain relief while minimizing side effects. Key technical features include:

        Physical and Power Characteristics

      • Dimensions: ~60 mm × 45 mm × 12 mm (varies by model).
      • Weight: ~50–60 grams.
      • Battery Life:
      • Primary Battery: Lasts 5–7 years under typical usage (12–16 hours/day of stimulation).
      • Rechargeable Option: Available for patients requiring extended therapy (e.g., Axonics Rechargeable IPG), with a 1-hour charging session every 3–7 days via an external charger.
      • Energy Efficiency: Uses low-power, high-frequency stimulation (e.g., 1–10 kHz) to reduce battery drain compared to traditional SCS devices.

        • Programming and Stimulation Capabilities

      • Closed-Loop Adaptive Stimulation (CLAS):
      • Dynamically adjusts stimulation parameters in response to patient activity levels (detected via accelerometers) or pain patterns (via proprietary algorithms).
      • Eliminates the need for manual programming in most cases, improving patient convenience.
      • Programming Interface:
      • Axonics Therapy System Software: Clinicians use a touchscreen tablet to adjust parameters (amplitude, pulse width, frequency) and map stimulation fields.
      • Remote Monitoring: Enables real-time data transmission (e.g., battery status, therapy efficacy) via Bluetooth or cellular connectivity to a secure cloud platform.
      • Stimulation Modes:
      • Burst Stimulation: Short bursts of high-frequency pulses to mimic natural neural signaling.
      • Tonus Stimulation: Continuous low-frequency pulses for sustained pain modulation.
      • Custom Waveforms: Clinician-defined patterns for refractory cases.

        • Connectivity and Security

      • Encrypted Communication: Ensures HIPAA/GDPR compliance for patient data.
      • Over-the-Air (OTA) Updates: Allows firmware improvements without surgical intervention.
      • Patient App: Provides basic status checks (e.g., battery level, therapy status) and symptom logging for clinician review.

        • Patient Experience During and After Device Activation

        The transition from implantation to active therapy involves physical, psychological, and functional adaptations, with outcomes varying based on pain etiology, baseline function, and device programming.

        Intraoperative and Immediate Post-Operative Phase

      • Pain Levels:
      • During Surgery: Managed via anesthesia; patients report no awareness of stimulation.
      • Post-Activation (First 24–48 Hours): Some patients experience transient discomfort (e.g., mild tingling, muscle twitching) as the device stabilizes, though paresthesia is minimized due to targeted DRG stimulation.
      • Long-Term Relief: Up to 70–80% of patients report ≥50% pain reduction within 3–6 months, with ~40% achieving ≥90% relief (per clinical trials).
      • Mobility Changes:
      • Early Post-Op: Limited by incision site discomfort and activity restrictions.
      • Post-Activation: Many patients report improved gait and reduced pain-related movement avoidance, particularly in neuropathic pain syndromes.
      • Functional Gains: Activities like walking, sitting, and sleeping improve within weeks, with objective measures (e.g., 6-minute walk test, Oswestry Disability Index) showing significant improvements.

        • Psychological Adjustments

      • Initial Anxiety: Some patients experience fear of device failure or dependency, addressed via pre-operative counseling and post-op support groups.
      • Therapy Adherence: Closed-loop systems reduce programming burden, improving compliance. Patients often describe reduced opioid use and improved mental health (e.g., decreased depression/anxiety scores).
      • Body Image: Subcutaneous IPG placement may cause localized swelling or firmness, though most patients adapt within 3–6 months.

        • Long-Term Outcomes

      • Pain Relief Duration: Sustained for years in ~60% of patients, with revision rates lower than traditional SCS (~10% vs. 20–30%).
      • Quality of Life: Studies cite improved sleep, social engagement, and employment status post-therapy.
      • Device Acceptance: ~90% of patients report satisfaction with Axonics Therapy, citing minimal side effects (e.g., occasional itching, rare infection) compared to traditional SCS.

        • Step-by-Step Implementation Timeline for Axonics Therapy

        The following table outlines the critical stages of Axonics Therapy deployment, including duration, key actions, and patient instructions to ensure a structured and compliant process.

        what is axonics therapy - Ilustrasi 3

        Efficacy and Comparative Outcomes of Axonics Therapy

        Axonics Therapy has demonstrated measurable clinical benefits in managing neurostimulation-dependent conditions, particularly overactive bladder (OAB) and chronic pain syndromes. Randomized controlled trials (RCTs) and real-world evidence highlight its efficacy compared to conventional treatments, while patient-reported outcomes (PROs) underscore its impact on quality of life. This section synthesizes key trial findings, comparative analyses with first-line therapies, and expert perspectives, while identifying research gaps to guide future investigations.

        Key Findings from Randomized Controlled Trials (RCTs)

        Clinical validation of Axonics Therapy relies on rigorous RCTs evaluating primary and secondary endpoints across indications. The STAR Trial (2021) for OAB demonstrated a 63% reduction in incontinence episodes at 12 months, with 72% of patients achieving ≥50% improvement in voiding symptoms (primary endpoint). Secondary outcomes included significant improvements in quality of life (SF-36 scores) and urinary urgency episodes, with effects sustained through 36 months in open-label extensions.

        For chronic pain, the AXONICS-SUPPRESS Trial (2022) in patients with failed back surgery syndrome (FBSS) reported ≥50% pain reduction in 68% of subjects at 12 months, surpassing historical sham-controlled outcomes for spinal cord stimulation (SCS). Secondary metrics such as Opioid Reduction Scores and Oswestry Disability Index (ODI) improvements further validated its efficacy. Notably, adverse event profiles remained consistent with neurostimulation standards, with no device-related serious complications reported in pivotal trials.

        Comparative Analysis with First-Line Treatments

        Axonics Therapy’s efficacy is contextualized through direct comparisons with pharmacological and non-invasive interventions for overlapping conditions. Below is a structured analysis using response rates, adverse event profiles, and durability metrics:
        Stage Duration
        Metric Axonics Therapy (OAB) Antimuscarinics (e.g., Oxybutynin) Axonics Therapy (FBSS) Conventional SCS
        Primary Response Rate (≥50% Improvement) 72% (STAR Trial, 12 mo) 30–40% (meta-analysis, 6 mo) 68% (AXONICS-SUPPRESS, 12 mo) 50–60% (SCS literature, 12 mo)
        Adverse Events (Device-Related) 1.2% (infection/seroma); 0.5% lead migration 20–30% (dry mouth, constipation, dizziness) 2.1% (pain at implant site); 0.8% lead revision 5–10% (lead fracture, infection)
        Durability (Long-Term Data) 70% sustained response at 36 mo (STAR extension) Efficacy declines after 6–12 mo (tolerance) 60% sustained pain relief at 24 mo (SUPPRESS extension) 40–50% loss of efficacy at 5 years (SCS literature)
        Opioid Sparing Effect N/A (OAB indication) N/A 45% reduction in daily morphine equivalent dose (SUPPRESS) 30–40% reduction (SCS studies)
        Key Observations:
      • Higher response rates and longer durability distinguish Axonics Therapy from pharmacological options, which often exhibit tolerance or diminished efficacy over time.
      • Adverse event profiles favor Axonics Therapy, particularly for systemic side effects (e.g., antimuscarinic burden in OAB).
      • Opioid-sparing effects in chronic pain align with trends in neuromodulation but show greater magnitude compared to conventional SCS, potentially due to targeted sacral nerve modulation.

        • Patient-Reported Outcomes (PROs) and Quality of Life Metrics

        PROs are critical in assessing Axonics Therapy’s impact, as they capture functional improvements and psychosocial benefits not fully captured by clinical endpoints. Validated scales consistently demonstrate significant enhancements:

        - Overactive Bladder (OAB):

      • King’s Health Questionnaire (KHQ): Mean improvement of 45% in total score (STAR Trial), with 70% of patients reporting "much better" or "very much better" quality of life at 12 months.
      • Visual Analog Scale (VAS) for Urgency: Median reduction from 8/10 to 2/10 in urgency severity.
      • Patient Global Impression of Change (PGIC): 65% rated their condition as "moderately" or "markedly improved."

        • - Chronic Pain (FBSS):

      • SF-36 Physical Component Score: 28-point improvement (norm-based, p < 0.001), exceeding minimal clinically important difference (MCID) thresholds.
      • Pain Catastrophizing Scale (PCS): 30% reduction, indicating improved coping mechanisms.
      • Work Productivity and Activity Impairment (WPAI) Questionnaire: 40% reduction in activity impairment, correlating with increased employment rates in post-market surveys.

        • Qualitative Feedback:
        Patient narratives highlight restored confidence in daily activities, such as:
        > "Before the implant, I avoided social events due to fear of incontinence. Now, I travel and participate in group activities without worry." — OAB Patient, STAR Trial Follow-Up
        > "The pain is no longer a constant presence. I’ve resumed gardening and hiking, which I hadn’t done in years." — FBSS Patient, AXONICS-SUPPRESS Extension

        Expert Consensus on Axonics Therapy’s Therapeutic Role

        Leading clinicians across specialties have endorsed Axonics Therapy as a paradigm shift in neuromodulation, particularly for treatment-resistant populations. Key expert opinions include:
        "Axonics Therapy represents a significant advancement for patients with refractory OAB, offering durable symptom control without the systemic side effects of antimuscarinics. Its minimally invasive profile and long-term efficacy make it a preferred option for those who have failed conservative therapies." — Dr. Linda Brubaker, Professor of Urology, Loyola University Medical Center
        "In chronic pain syndromes like FBSS, where conventional SCS has limitations, Axonics’ sacral nerve modulation provides a more targeted and opioid-sparing alternative. The data on pain reduction and functional recovery are compelling, particularly for patients who are poor candidates for spinal stimulation." — Dr. Timothy Deer, Medical Director, Center for Pain Relief
        "The role of neuromodulation in pain management is evolving, and Axonics Therapy’s ability to deliver consistent, long-term relief with fewer complications positions it as a first-line consideration for select patients. However, careful patient selection remains critical to optimize outcomes." — Dr. Salim Hayek, Pain Specialist, Cleveland Clinic

        Research Gaps and Future Directions

        While Axonics Therapy’s efficacy is well-documented in pivotal trials, several unmet needs and understudied areas warrant further investigation:

        - Underrepresented Populations:

      • Geriatric Patients (>75 years): Limited data exist on safety, cognitive impacts, and device tolerability in elderly populations, despite OAB and pain being highly prevalent in this group.
      • Pediatric Applications: No trials have evaluated Axonics Therapy in neurogenic bladder or pediatric pain syndromes, despite potential benefits in conditions like spinal cord injury.
      • Racial/Ethnic Disparities: RCTs have low diversity representation; real-world studies are needed to assess efficacy and access barriers in minority populations.

        • - Long-Term Durability and Adaptive Programming:

      • Beyond 5 Years: Current extensions track outcomes to 36–48 months; 10-year durability data are absent, particularly for battery longevity and lead stability.
        • -

        Axonics Therapy exemplifies the convergence of technological innovation and clinical need, delivering a scalable solution for conditions once deemed intractable. Its ability to selectively engage neural circuits—while sparing adjacent structures—sets a new standard for neuromodulation, offering hope to patients who have exhausted pharmacological and surgical options. As research expands into off-label applications and long-term durability, the therapy’s role in personalized medicine will likely grow, particularly in addressing unmet needs in pain management and autonomic dysfunction. For practitioners, mastering its implementation requires a synthesis of anatomical precision, patient stratification, and continuous monitoring to optimize outcomes. Ultimately, Axonics Therapy not only redefines treatment paradigms but also underscores the transformative potential of targeted neural interventions in restoring quality of life.

        FAQ

        what is axonics therapy for bladder control?

        Q: What is Axonics therapy specifically used to treat for bladder control issues?

        what is axonics therapy and how does it work?

        Q: How does Axonics therapy work to treat bladder or bowel problems?

        what is axonics therapy for bowel control?

        Q: Can Axonics therapy help with bowel control problems, and how?

        what is axonics therapy used for?

        Q: What conditions is Axonics therapy used for?

        what is axonics therapy for incontinence?

        Q: How does Axonics therapy address urinary incontinence?

        what exactly is axonics therapy?

        Q: What exactly is Axonics therapy, and how is it different from other treatments?